miR-21 may Act as a Potential Mediator Between Inflammation and Abnormal Bone Formation in Ankylosing Spondylitis Based on TNF-α Concentration-Dependent Manner Through the JAK2/STAT3 Pathway

被引:27
|
作者
Zou, Yu-Cong [1 ]
Yan, Li-Man [2 ]
Gao, Yan-Ping [3 ]
Wang, Zhi-Yun [4 ]
Liu, Gang [1 ]
机构
[1] Southern Med Univ, Affiliated Hosp 3, Dept Rehabil Med, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China
[3] Southern Med Univ, Affiliated Hosp 3, Dept TCM Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China
[4] Southern Med Univ, ShunDe Hosp, Foshan, Guangdong, Peoples R China
来源
DOSE-RESPONSE | 2020年 / 18卷 / 01期
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
ankylosing spondylitis; miR-21; TNF-alpha; JAK; STAT-3; signaling; NECROSIS-FACTOR-ALPHA; RADIOGRAPHIC PROGRESSION; OSTEOGENIC DIFFERENTIATION; SIGNALING PATHWAY; STEM-CELLS; MICRORNA-21; EXPRESSION; PROLIFERATION; POLARIZATION; INHIBITORS;
D O I
10.1177/1559325819901239
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To explore the role of microRNA (miR-21) in new bone formation in ankylosing spondylitis (AS) as mediated by different concentration of tumor necrosis factor-alpha (TNF-alpha). Methods: Fibroblasts isolated from the hips of patients with AS were induced to osteogenesis. These cells were then stimulated with varying concentrations of TNF-alpha. MicroRNA-21 expressions were evaluated using reverse transcription-polymerase chain reaction (RT-PCR) and osteogenesis was detected via Alizarin Red S (ARS) staining and measurement of alkaline phosphatase (ALP) activity. Relative expressions of p-STAT3, Nuclear STAT3, cytoplasm STAT3, Runx2, BMP2, osteopontin, osteocalcin, and LC3B in AS fibroblasts were measured after exposure to different concentrations of TNF-alpha. The STAT3-inhibiting small interfering RNA allowed further exploration on its impact on miR-21 and primary miR-21 expressions. A proteoglycan-induced arthritis (PGIA) Balb/c mouse model was established in order to monitor sacroiliac joint (SIJ) inflammation and subsequent damage through magnetic resonance image. Serum miR-21 and TNF-alpha expressions were evaluated using RT-PCR and enzyme-linked immunosorbent assay. At week 16, mice models were transfected intravenously with miR-21 overexpressing agomir and miR-21 inhibiting antagomir for 7 successive days. The rate of abnormal bone formation at SIJ was evaluated using microcomputed tomography and hematoxylin and eosin staining at week 24. Western blot analysis enabled quantification of STAT-3, JAK-2, and interleukin (IL)-17A expressions present in the SIJ. Results: The in vitro miR-21 expression and osteogenesis activity were noted to be augmented in the setting of low TNF-alpha concentrations (0.01-0.1 ng/mL) while they were depressed in settings with higher TNF-alpha concentrations (1-10 ng/mL). Samples with the most distinct ARS manifestation and ALP activity as well as the highest miR-21 expressions were those who received 0.1 ng/mL of TNF-alpha. Primary miR-21 was found to be notable raised by Si-STAT3, while the converse effect was seen in mature miR-21 expressions. Intravenous injection of exogenous miR-21 contributed to new bone formation and significantly elevated expressions of STAT3, JAK2, and IL-17 in PGIA mice. Conclusions: The results revealed that miR-21 may act as a potential mediator between new bone formation and inflammation in AS.
引用
收藏
页数:11
相关论文
共 2 条
  • [1] DUSP1 regulates the JAK2/STAT3 signaling pathway through targeting miR-21 in cervical cancer cells
    Chen, Hailin
    Ren, Songsen
    Wan, Hui
    Wei, Wengong
    Luo, Yi
    Cai, Meiling
    CELLULAR AND MOLECULAR BIOLOGY, 2023, 69 (08) : 40 - 44
  • [2] Hypoxic-preconditioned mesenchymal stem cell-derived small extracellular vesicles promote the recovery of spinal cord injury by affecting the phenotype of astrocytes through the miR-21/JAK2/STAT3 pathway
    Yang, Zhelun
    Liang, Zeyan
    Rao, Jian
    Xie, Haishu
    Zhou, Maochao
    Xu, Xiongjie
    Lin, Yike
    Lin, Fabin
    Wang, Chunhua
    Chen, Chunmei
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (03)